Bontempo Ohly Capital Mgmt LLC Purchases 13,649 Shares of Johnson & Johnson $JNJ

Key Points

• Bontempo Ohly Capital Mgmt LLC increased its stake in Johnson & Johnson by 88.4%, acquiring 13,649 additional shares, bringing its total holdings to 29,088 shares valued at approximately $4.82 million.
• Johnson & Johnson recently reported a quarterly earnings result of $2.77 EPS, exceeding analysts' estimates, and a revenue of $23.74 billion, which marks a 5.8% increase from the previous year.
• The company declared a quarterly dividend of $1.30, representing an annualized yield of 2.9% and a payout ratio of 55.61%.

Bontempo Ohly Capital Mgmt LLC boosted its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 88.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,088 shares of the company's stock after acquiring an additional 13,649 shares during the period. Johnson & Johnson accounts for 2.3% of Bontempo Ohly Capital Mgmt LLC's portfolio, making the stock its 5th largest position. Bontempo Ohly Capital Mgmt LLC's holdings in Johnson & Johnson were worth $4,824,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in JNJ. CBIZ Investment Advisory Services LLC grew its position in shares of Johnson & Johnson by 75.1% during the first quarter. CBIZ Investment Advisory Services LLC now owns 627 shares of the company's stock worth $104,000 after acquiring an additional 269 shares during the last quarter. Modern Wealth Management LLC lifted its stake in Johnson & Johnson by 30.1% during the first quarter. Modern Wealth Management LLC now owns 40,596 shares of the company's stock valued at $6,733,000 after buying an additional 9,392 shares in the last quarter. Jones Financial Companies Lllp lifted its position in shares of Johnson & Johnson by 22.5% in the first quarter. Jones Financial Companies Lllp now owns 559,577 shares of the company's stock worth $91,864,000 after purchasing an additional 102,830 shares in the last quarter. Silicon Valley Capital Partners lifted its position in shares of Johnson & Johnson by 196.9% in the first quarter. Silicon Valley Capital Partners now owns 10,672 shares of the company's stock worth $1,747,000 after purchasing an additional 7,077 shares in the last quarter. Finally, Strs Ohio acquired a new position in Johnson & Johnson in the first quarter worth approximately $136,434,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $178.40 on Friday. The stock has a 50-day simple moving average of $170.36 and a 200 day simple moving average of $161.22. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $181.16. The stock has a market capitalization of $429.65 billion, a price-to-earnings ratio of 19.08, a P/E/G ratio of 2.24 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the previous year, the business posted $2.82 earnings per share. The firm's revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Analysts Set New Price Targets

Several brokerages have commented on JNJ. Citigroup increased their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a report on Thursday, August 21st. Barclays lifted their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Morgan Stanley lifted their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Finally, Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $176.29.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.